A Case of Resistance to Selective RET-TKI Therapy With Pleural-Genotyped MET Amplification and Response to Crizotinib

被引：1
作者：
Chen, Kaiyan [1 ,2 ,3 ]
Zhang, Fanrong [1 ,4 ]
Pan, Guoqiang [1 ,2 ,3 ,5 ]
Sheng, Jiamin [1 ,2 ,3 ,5 ]
Ye, Junyi [6 ]
Xu, Yanjun [1 ,2 ,3 ]
Yu, Xiaoqing [1 ,2 ,3 ]
Huang, Zhiyu [1 ,2 ,3 ]
Fan, Yun [1 ,2 ,3 ]
机构：
[1] Univ Chinese Acad Sci, Canc Hosp, Zhejiang Canc Hosp, Hangzhou, Peoples R China
[2] Chinese Acad Sci, Inst Canc & Basic Med, Hangzhou, Peoples R China
[3] Zhejiang Canc Hosp, Dept Thorac Med Oncol, Hangzhou, Peoples R China
[4] Zhejiang Canc Hosp, Dept Breast Surg, Hangzhou, Peoples R China
[5] Wenzhou Med Univ, Clin Med Coll 1, Dept Oncol, Wenzhou, Peoples R China
[6] Bioinformat Dept, Burning Rock Biotech, Guangzhou, Peoples R China
来源：
CLINICAL LUNG CANCER | 2021年 / 22卷 / 01期
关键词：
Crizotinib; MET; Non-small-cell lung cancer; RET; Resistance; CELL LUNG-CANCER; ACQUIRED-RESISTANCE; OPEN-LABEL; CARCINOMAS; PHASE-2;
D O I：
10.1016/j.cllc.2020.07.007
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
[No abstract available]
引用
收藏
页码：E1 / E4
页数：4
相关论文
共 15 条
  • [1] MIXED SMALL-CELL AND NON-SMALL CELL LUNG-CANCER
    ADELSTEIN, DJ
    TOMASHEFSKI, JF
    SNOW, NJ
    HORRIGAN, TP
    HINES, JD
    [J]. CHEST, 1986, 89 (05) : 699 - 704
  • [2] Transformation to small cell lung cancer as a mechanism of resistance to immunotherapy in non-small cell lung cancer
    Bar, Jair
    Ofek, Efrat
    Barshack, Iris
    Gottfried, Teodor
    Zadok, Oranit
    Kamer, Iris
    Urban, Damien
    Perelman, Marina
    Onn, Amir
    [J]. LUNG CANCER, 2019, 138 : 109 - 115
  • [3] Acquired resistance to TKIs in solid tumours: learning from lung cancer
    Camidge, D. Ross
    Pao, William
    Sequist, Lecia V.
    [J]. NATURE REVIEWS CLINICAL ONCOLOGY, 2014, 11 (08) : 473 - 481
  • [4] Cheng Y., 2019, ANN ONCOL, V30, pv711, DOI DOI 10.1093/ANNONC/MDZ264.002
  • [5] Cabozantinib in patients with advanced RET-rearranged non-small-cell lung cancer: an open-label, single-centre, phase 2, single-arm trial
    Drilon, Alexander
    Rekhtman, Natasha
    Arcila, Maria
    Wang, Lu
    Ni, Andy
    Albano, Melanie
    Van Voorthuysen, Martine
    Somwar, Romel
    Smith, Roger S.
    Montecalvo, Joseph
    Plodkowski, Andrew
    Ginsberg, Michelle S.
    Riely, Gregory J.
    Rudin, Charles M.
    Ladanyi, Marc
    Kris, Mark G.
    [J]. LANCET ONCOLOGY, 2016, 17 (12) : 1653 - 1660
  • [6] A phase 1 study of LOXO-292, a potent and highly selective RET inhibitor, in patients with RET-altered cancers.
    Drilon, Alexander E.
    Subbiah, Vivek
    Oxnard, Geoffrey R.
    Bauer, Todd Michael
    Velcheti, Vamsidhar
    Lakhani, Nehal J.
    Besse, Benjamin
    Park, Keunchil
    Patel, Jyoti D.
    Cabanillas, Maria E.
    Johnson, Melissa Lynne
    Reckamp, Karen L.
    Boni, Valentina
    Loong, Herbert H. F.
    Schlumberger, Martin
    Solomon, Ben
    Cruickshank, Scott
    Rothenberg, Stephen M.
    Shah, Manisha H.
    Wirth, Lori J.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [7] Gainor JF, 2019, J CLIN ONCOL, V37
  • [8] Targeting RET in Patients With RET-Rearranged Lung Cancers: Results From the Global, Multicenter RET Registry
    Gautschi, Oliver
    Milia, Julie
    Filleron, Thomas
    Wolf, Juergen
    Carbone, David P.
    Owen, Dwight
    Camidge, Ross
    Narayanan, Vignhesh
    Doebele, Robert C.
    Besse, Benjamin
    Remon-Masip, Jordi
    Janne, Pasi A.
    Awad, Mark M.
    Peled, Nir
    Byoung, Chul-Cho
    Karp, Daniel D.
    Van Den Heuvel, Michael
    Wakelee, Heather A.
    Neal, Joel W.
    Mok, Tony S. K.
    Yang, James C. H.
    Ou, Sai-Hong Ignatius
    Pall, Georg
    Froesch, Patrizia
    Zalcman, Gerard
    Gandara, David R.
    Riess, JonathanW.
    Velcheti, Vamsidhar
    Zeidler, Kristin
    Diebold, Joachim
    Frueh, Martin
    Michels, Sebastian
    Monnet, Isabelle
    Popat, Sanjay
    Rosell, Rafael
    Karachaliou, Niki
    Rothschild, Sacha I.
    Shih, Jin-Yuan
    Warth, Arne
    Muley, Thomas
    Cabillic, Florian
    Mazieres, Julien
    Drilon, Alexander
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (13) : 1403 - +
  • [9] Effect of Anlotinib as a Third-Line or Further Treatment on Overall Survival of Patients With Advanced Non-Small Cell Lung Cancer The ALTER 0303 Phase 3 Randomized Clinical Trial
    Han, Baohui
    Li, Kai
    Wang, Qiming
    Zhang, Li
    Shi, Jianhua
    Wang, Zhehai
    Cheng, Ying
    He, Jianxing
    Shi, Yuankai
    Zhao, Yizhuo
    Yu, Hao
    Zhao, Yang
    Chen, Weiqiang
    Luo, Yi
    Wu, Lin
    Wang, Xiuwen
    Pirker, Robert
    Nan, Kejun
    Jin, Faguang
    Dong, Jian
    Li, Baolan
    Sun, Yan
    [J]. JAMA ONCOLOGY, 2018, 4 (11) : 1569 - 1575
  • [10] Clonal History and Genetic Predictors of Transformation Into Small-Cell Carcinomas From Lung Adenocarcinomas
    Lee, June-Koo
    Lee, Junehawk
    Kim, Sehui
    Kim, Soyeon
    Youk, Jeonghwan
    Park, Seongyeol
    An, Yohan
    Keam, Bhumsuk
    Kim, Dong-Wan
    Heo, Dae Seog
    Kim, Young Tae
    Kim, Jin-Soo
    Kim, Se Hyun
    Lee, Jong Seok
    Lee, Se-Hoon
    Park, Keunchil
    Ku, Ja-Lok
    Jeon, Yoon Kyung
    Chung, Doo Hyun
    Park, Peter J.
    Kim, Joon
    Kim, Tae Min
    Ju, Young Seok
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (26) : 3065 - +
12